Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Apr 20, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the...
Apr 14, 2016Fourth Comic Book in the Series “Medikidz Explain Epilepsy” Launching at the 2016 National Walk for Epilepsy in Washington, D.C.-
Apr 11, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global...
- Apr 6, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology...
-
Mar 18, 2016--Helsinn Therapeutics Inc. to obtain all rights to promote and distribute AKYNZEO® (netupitant/palonosetron) --
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd ,...
-
Feb 10, 2016Pivotal Data Led to Recent FDA Approval for This Indication
Eisai Inc. announced today that results from its pivotal Phase 3 study (Study 309) investigating the use of Halaven® (eribulin mesylate) Injection (0.5 mg per mL) in certain types of soft tissue...
-
Jan 29, 2016- Halaven is the first and only single agent to prolong overall survival in patients with previously treated advanced (unresectable or metastatic) liposarcoma in a Phase 3 trial
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or...
-
Jan 17, 2016Supplemental application based on progression-free survival data from Study 205, a three-arm Phase 2 study comparing lenvatinib in combination with everolimus, everolimus alone and lenvatinib alone in these patients
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for lenvatinib for the potential treatment...
-
Dec 9, 2015
Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin...
- Dec 2, 2015
Eisai Inc. announced today that 21 posters highlighting perampanel data and an interim analysis from the first and largest caregiver burden study in epilepsy will be presented at the 69th Annual...
